Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Byetta Archives
Print | Email | Share | Comments (1)

Research Disputes FDA Claim that Exenatide Increase Risk of Acute Pancreatitis

Jun 19, 2009

The study results, presented at the recent ADA conference, showed that only 0.44 percent of exenatide users experienced an episode of acute pancreatitis.

In 2008, the U.S. Food and Drug Administration published strong warnings that the type 2 diabetes drug exenatide (trade name Byetta) might increase risk of acute pancreatitis, a painful inflammation of the pancreas. The FDA's action came in the wake of reports that 30 exenatide users had come down with pancreatitis and that six of them had died from the condition.

Now, however, a study published by researchers from Medco Health Solutions, Inc., says that exenatide users run no greater risk of developing pancreatitis than type 2s who take neither drug.

The study results, presented at the recent 69th Scientific Sessions of the American Diabetes Association (ADA), showed that only 0.44 percent of exenatide users experienced an episode of acute pancreatitis. Among sitagliptin users, only 0.28 percent had such episodes. Among the control group of type 2s, however, who had never taken either drug, the rate of incidence was 0.39 percent.   

The study results were based on tracking the pharmacy and medical claims of 123,621 non-insulin-using type 2s for 540 days  and observing which ones came down with pancreatitis:

  • 9,260 patients were exenatide users
  • 2,143 patients were on sitagliptin
  • 112,218 patients, the control group, used neither drug but were taking a medication designed to control blood glucose
  • No patient in the study had a history of pancreatitis, hepatitis or alcohol abuse
  • The patients' ages ranged from 18 to 63 years

The Medco study is the first to lend scientific support to Eli Lilly and Co., Byetta's maker. Lilly has questioned the FDA's statistical reasoning, citing the extremely low percentage of pancreatitis cases associated with the drug.

For more information on the study, visit Medco


Categories: Blood Glucose, Blood Sugar, Byetta, Community, Diabetes, Diabetes, Food, Insulin, Research, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 1 comment - Jun 19, 2009

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.